8 April 2014
Valiance and RMM join Second Closing bringing total round to $72.5 million; New Board Member appointed.
1 April 2014InDex Pharmaceuticals and Almirall enter into a license agreement for European rights of the phase III drug candidate Kappaproct®
InDex Pharmaceuticals and Almirall announced today that they have signed a license agreement for the European marketing rights to the drug candidate Kappaproct®. Under the terms of the agreement, InDex is eligible for an upfront payment as well as success driven milestone payments with a total deal value that could exceed EUR100M. InDex is also entitled to receive double digit royalties from Almirall on the European net sales of Kappaproct®.
25 March 2014Axonics Modulation Technologies Announces $32.6 Million Series A Financing Led by Edmond De Rothschild Investment Partners
Axonics Modulation Technologies, Inc., a developer of novel implantable neuromodulation technology, announced today that it has completed a $32.6 million Series A preferred stock financing.
28 February 2014Unilabs and Diagnoplex SA announce the Swiss market launch of Colox®, a non-invasive colon cancer screening test
Unilabs, a leading supplier of clinical laboratory and medical diagnostic imaging services in Europe and Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer announced today the Swiss market launch of Colox®, a non-invasive screening test for colorectal cancer. Colox® is offered as a service by Unilabs’ clinical diagnostic service laboratories in Switzerland. Additional countries within Unilabs’ network of laboratories are planned to follow in 2014.
25 February 2014
InDex Pharmaceuticals today announced the successful closing of a USD 20 million / EUR 15 million new rights issue. NeoMed led the oversubscribed financing round while current shareholders participated with 75% of the invested capital.